Skip to Content
Merck
CN

GF07844249

Ruthenium

Ruthenium, foil, 10x10mm, thickness 1.0mm, 99.9%

Synonym(s):

Ruthenium, RU000220

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
Ru
CAS Number:
Molecular Weight:
101.07
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12141739
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

99.9%

form

foil

manufacturer/tradename

Goodfellow 078-442-49

resistivity

7.1 μΩ-cm, 0°C

L × W × thickness

10 mm × 10 mm × 1.0 mm

bp

3900 °C (lit.)

mp

2310 °C (lit.)

density

12.45 g/cm3 (lit.)

SMILES string

[Ru]

InChI

1S/Ru

InChI key

KJTLSVCANCCWHF-UHFFFAOYSA-N

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow


Still not finding the right product?

Explore all of our products under Ruthenium


Storage Class

13 - Non Combustible Solids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



E Tfouni et al.
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with



Global Trade Item Number

SKUGTIN
GF07844249-1EA04061825339399
GF07844249-2EA04061829504991